An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatm ...
A Multicenter Extension Study to Evaluate the Long-Term Safety and Durability of the Therapeutic Effect of LUM001, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome A Multicenter Extension Study to Evaluate the Long-Term Safety and Durability of the Therapeutic Eff ...
Alagille Syndrome
Drug: LUM001 (Maralixibat)
Mirum Pharmaceuticals, Inc.
Lumena Pharmaceuticals, Inc.;Childhood Liver Disease Research and Education Network
An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome (ALGS) An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatm ...
A Multicentre Extension Study to Evaluate the Long-Term Safety and Durability of the Therapeutic Effect of LUM001 Also Known as Maralixibat (MRX), an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome A Multicentre Extension Study to Evaluate the Long-Term Safety and Durability of the Therapeutic Eff ...